Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Rhea-AI Summary

Aldeyra Therapeutics (ALDX) has announced its participation in the Disruptive Innovations Symposium at the OSN New York Retina 2024 Meeting, scheduled for November 8-10, 2024. Dr. Tomasz Stryjewski, Chief Medical Advisor - Retina, will present on the Phase 2/3 clinical development of ADX-2191 for retinitis pigmentosa treatment on November 8, 2024, from 3:30-5:30 p.m. ET.

The company specializes in developing therapies for immune-mediated and metabolic diseases, focusing on RASP modulators including ADX-629, ADX-248, ADX-743, and ADX-631. Their late-stage candidates include reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for retinitis pigmentosa.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.

Dr. Stryjewski will provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 – 5:30 p.m. ET on Friday, November 8, 2024.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241031692801/en/

Investor & Media Contact:

Laura Nichols

Tel: (781) 257-3060

investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When will Aldeyra (ALDX) present at the OSN New York Retina 2024 Meeting?

Aldeyra will present on Friday, November 8, 2024, from 3:30 – 5:30 p.m. ET during the Disruptive Innovations Symposium at the OSN New York Retina 2024 Meeting.

What will be the focus of Aldeyra's (ALDX) presentation at the OSN New York Retina 2024 Meeting?

The presentation will focus on the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa treatment.

What are Aldeyra's (ALDX) main late-stage product candidates?

Aldeyra's late-stage product candidates are reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinitis pigmentosa treatment.

Which RASP modulators is Aldeyra (ALDX) currently developing?

Aldeyra is developing RASP modulators including ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for immune-mediated and metabolic diseases.